PharmaMar and Chugai Agree to Terms for Early Termination of the License Agreement for Zepsyre® in Japan
WFMJ,
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
SOURCE PharmaMar MADRID PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3…
PR Newswire MADRID, June 26, 2018 MADRID, June 26, 2018 /PRNewswire/ -- PharmaMar regains all its rights for Zepsyre® in Japan…
/PRNewswire/ -- PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000…
/PRNewswire/ -- PharmaMar regains all its rights for Zepsyre® in Japan with immediate effect and receives a payment of €3,000,000…
/PRNewswire/ -- PharmaMar regains all its rights for Zepsyre ® in Japan with immediate effect and receives a payment of €3,000,00…
Madrid, 26th of June 2018.- On April 27th, 2018 PharmaMar (MSE:PHM) reported to National Securities Market Commission that…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
Information contained on this page is provided by an independent third-party content provider.
SOURCE PharmaMar MADRID PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has…
PR Newswire MADRID, May 29, 2018 MADRID, May 29, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today that the…
/PRNewswire/ -- PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the…
/PRNewswire/ -- PharmaMar (MCE: PHM ) has announced today that the Independent Data Monitoring Committee (IDMC) has notified…
PharmaMar (MSE:PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its…
Pharma Mar SA (via noodls) / PharmaMar initiates a pivotal Phase III ATLANTIS study with PM1183 in combination with doxorubicin…
Pharma Mar SA (via noodls) / Comisión Nacional del Mercado de Valores Att. Director del Área de Mercados C/Edison núm.
( Pharmamar ) PharmaMar today announced data from a Phase 1b study of the transcriptional inhibitor PM1183 in combination with…
MADRID January 13 2015 PRNewswire The unparalleled results obtained in the Phase Ib study support the start of a headtohead…
Madrid (ots/PRNewswire) - - Die beispiellosen, bei der Phase-Ib-Studie erhaltenen Ergebnisse sprechen für den Beginn einer…
( Pharmamar ) Data from a Phase 1b study demonstrate a marked anti-tumor activity in patients with relapsed SCLC treated with…